PMID- 38322847
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240210
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 10
IP  - 3
DP  - 2024 Feb 15
TI  - In vitro and Ex vivo study targeting the development of a Lavandula stoechas L. 
      (Ustukhuddus) loaded Unani Transdermal patch: Implication of Unani Medicine in 
      the treatment of Nisyan (Dementia).
PG  - e25284
LID - 10.1016/j.heliyon.2024.e25284 [doi]
LID - e25284
AB  - Ustukhuddus (Lavandula stoechas L.) has been extensively used orally and 
      topically in treating various neurological disorders, including dementia. The 
      optimum potential of traditional dosage forms of Ustukhuddus is limited for 
      various reasons. Transdermal drug delivery system (TDDS) is a novel means of drug 
      delivery and is known to overcome the drawbacks associated with traditional 
      dosage forms. The current study aimed at fabricating and evaluating Ustukhuddus 
      hydro-alcoholic extract (UHAE) and essential oil (UEO) loaded matrix-type 
      transdermal patches having a combination of hydrophilic - hydroxyl propyl methyl 
      cellulose (HPMC) and hydrophobic - ethyl cellulose (EC) polymers. ATR-FTIR, DSC, 
      XRD, and SEM analysis were carried out to study drug-polymer interactions, 
      confirming the formation of developed patches and drug compatibility with 
      excipients. We assessed the fabricated patches to evaluate their physicochemical 
      properties, in vitro drug release, and permeation characteristics via ex vivo 
      experiments. The physicochemical characteristics of patches showcased the 
      development of good and stable films with clarity, smoothness, homogeneity, 
      optimum flexibility and free from causing skin irritancy or sensitization. In 
      vitro drug release and ex vivo permeation profile of developed patches were 
      evaluated employing Franz diffusion cells. UHAE and UEO patches exhibited a 
      cumulative drug release of 81.61 and 85.24 %, respectively, in a 
      sustained-release manner and followed non-Fickian release mechanisms. The ex vivo 
      permeation data revealed 66.82 % and 76.41 % of drug permeated from UHAE and UEO 
      patches, respectively. The current research suggests that the formulated patches 
      are more suitable for TDDS and hold potential significance in the treatment of 
      dementia, contributing to enhanced patient compliance, thereby highlighting the 
      implication of Unani Medicine in Nisyan (Dementia) treatment.
CI  - (c) 2024 The Authors.
FAU - Fathima A, Farhath
AU  - Fathima A F
AD  - Regional Research Institute of Unani Medicine, Chennai, 600013, India.
FAU - Khan, Imran
AU  - Khan I
AD  - National Institute of Unani Medicine, Bengaluru, 560091, India.
FAU - Irfhan N, Mohammed
AU  - Irfhan N M
AD  - Government Unani Medical College, Chennai, 600106, India.
FAU - Ahmed N, Zaheer
AU  - Ahmed N Z
AD  - Central Council for Research in Unani Medicine, New Delhi, 110025, India.
FAU - Anwar, Noman
AU  - Anwar N
AD  - Regional Research Institute of Unani Medicine, Chennai, 600013, India.
FAU - Khan, Mohd Shahnawaz
AU  - Khan MS
AD  - Department of Biochemistry, College of Science, King Saud University, Riyadh, 
      Kingdom of Saudi Arabia.
FAU - Yadav, Dharmendra Kumar
AU  - Yadav DK
AD  - Gachon Institute of Pharmaceutical Science and Department of Pharmacy, College of 
      Pharmacy, Gachon University, Incheon, Republic of Korea.
FAU - Shamsi, Shariq
AU  - Shamsi S
AD  - National Institute of Unani Medicine, Bengaluru, 560091, India.
FAU - Shamsi, Anas
AU  - Shamsi A
AD  - Centre of Medical and Bio-allied Health Sciences Research, Ajman University, 
      United Arab Emirates.
LA  - eng
PT  - Journal Article
DEP - 20240126
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10845912
OTO - NOTNLM
OT  - Essential oil
OT  - Ex vivo permeation
OT  - Skin irritation
OT  - Sustained-release
OT  - Unani transdermal patch
OT  - Ustukhuddus
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/02/07 06:43
MHDA- 2024/02/07 06:44
PMCR- 2024/01/26
CRDT- 2024/02/07 04:08
PHST- 2023/10/30 00:00 [received]
PHST- 2024/01/20 00:00 [revised]
PHST- 2024/01/24 00:00 [accepted]
PHST- 2024/02/07 06:44 [medline]
PHST- 2024/02/07 06:43 [pubmed]
PHST- 2024/02/07 04:08 [entrez]
PHST- 2024/01/26 00:00 [pmc-release]
AID - S2405-8440(24)01315-X [pii]
AID - e25284 [pii]
AID - 10.1016/j.heliyon.2024.e25284 [doi]
PST - epublish
SO  - Heliyon. 2024 Jan 26;10(3):e25284. doi: 10.1016/j.heliyon.2024.e25284. 
      eCollection 2024 Feb 15.